Portfolio company
ICM
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
ICM develops adeno-associated virus gene therapies to treat patients with degenerative diseases such as osteoarthritis and retinal degeneration.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ikarovec
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.
Coave Therapeutics
The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.
Adverum Biotechnologies
The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.
InGel Therapeutics
The company develops stem-cell therapies and biodegradable hydrogels for patients suffering from retinal degeneration and blinding diseases like retinitis pigmentosa.
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
Spur Therapeutics
This company develops adeno-associated virus gene therapies to treat chronic conditions including Gaucher disease and Parkinson's disease for patients with inherited genetic disorders.
Nionyx Bio
The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.